At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 145 enrolled
Drug / intervention
Pazopanib +1 moredrug
Likely dose
Pazopanib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian Women Who Have Not Progressed After First-line Chemotherapy for Advanced Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma - An Extension Study to VEG110655
In Brief
A Phase 2 clinical trial evaluating Pazopanib and Placebo comparator for Neoplasms, Ovarian. Completed, enrolled 145 participants across 15 sites in 4 countries.
Detailed Summary
This is a study to determine whether therapy with pazopanib is effective and safe in Asian women with epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer has not progressed on first-line chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Ovarian
CountriesChina, Hong Kong, South Korea, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedOct 2010
Primary CompletionOct 2012
Study CompletionJan 2014
TodayJul 2026
First PostedOct 25, 2010
Enrollment StartSep 1, 2010
Primary CompletionOct 1, 2012
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.7 years ago
Interventions
Pazopanibdrug
Pazopanib 800 mg daily for 24 months
Placebo comparatordrug
Placebo 800 mg daily for 24 months